New drug plus radiation for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug (S-531011) combined with a special type of radiation (RadScopal) for people with colorectal cancer that has spread and is no longer responding to standard chemotherapy. The treatment aims to shrink tumors and help your immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have colorectal cancer that is not the MSI-H type and has spread or cannot be removed by surgery
- You have already received at least three types of chemotherapy (fluoropyrimidine, oxaliplatin, and irinotecan)
- You have at least two tumors that can be treated with a special radiation plan (one tumor gets a high dose, the other gets a low dose)
- Your overall health is good (able to do daily activities without help or with minimal help)
- Your blood counts and organ function (kidney, liver) are within acceptable levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving focused radiation (SBRT) together with fruquintinib and immune drugs (PD-1/CTLA-4) can control advanced, hard-to-remove colorectal cancer. It is for people whose cancer has grown despite standard first- and second-line chemotherapy.
This trial tests a new combination—an immunotherapy drug (cadonilimab) plus a targeted anti-angiogenesis pill (fruquintinib) and focused radiation (SBRT)—for people with MSS colorectal cancer that has progressed after at least two prior treatments. The goal is to see if this triple approach can help shrink or control the cancer better than standard options.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.
This trial tests a combination of targeted radiation therapy, an immune-boosting drug, and two chemotherapy drugs for colorectal cancer that has spread or come back after two rounds of prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.